Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Immix Biopharma, Inc.IMMX · Entity 4958 | Director | May 22, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Immix Biopharma, Inc.
Report date May 22, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 181,004 |
Reported balance
After 2026-05-22 transaction · row 1
1 source rowRow 1 · 2026-05-22 · Grant · Acquired 6,250 · Balance 181,004 F1: The Reporting Person was granted 6,250 restricted stock units ("RSUs") pursuant to the Issuer's 2021 Equity Incentive Plan, which RSUs will vest in full on the earlier of (i) the one-year anniversary of the date of grant, and (ii) the date that the Issuer's 2027 annual meeting of stockholders (the "2027 Annual Meeting") is held, subject to the Reporting Person's continued service with the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.78 · Expires 2036-05-22 | Direct | 12,500 |
Reported balance
After 2026-05-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-22 · Grant · Acquired 12,500 · Balance 12,500 F2: The stock option will vest in substantially equal monthly installments over the 12 months following the date of grant (or, in the event the 2027 Annual Meeting occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the stock option will vest on the date of such 2027 Annual Meeting), subject to the Reporting Person's continued service on the Issuer's Board through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted 6,250 restricted stock units ("RSUs") pursuant to the Issuer's 2021 Equity Incentive Plan, which RSUs will vest in full on the earlier of (i) the one-year anniversary of the date of grant, and (ii) the date that the Issuer's 2027 annual meeting of stockholders (the "2027 Annual Meeting") is held, subject to the Reporting Person's continued service with the Issuer.
F2: The stock option will vest in substantially equal monthly installments over the 12 months following the date of grant (or, in the event the 2027 Annual Meeting occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the stock option will vest on the date of such 2027 Annual Meeting), subject to the Reporting Person's continued service on the Issuer's Board through the applicable vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Prometheus Biosciences, Inc.
Report date June 16, 2023 · Filed June 16, 2023
Section 16 reporting ended · disclosed 2023-06-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-06-16 transaction · row 1
1 source rowRow 1 · 2023-06-16 · Disposition to issuer · Disposed 2,674 · Balance 0 F1: Includes 2,174 restricted stock units. F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,... (Continued in Footnote 3) F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.70 · Expires 2031-02-04 | Direct | 0 |
Reported balance
After 2023-06-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-16 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,... (Continued in Footnote 3) F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.32 · Expires 2031-11-13 | Direct | 0 |
Reported balance
After 2023-06-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-06-16 · Disposition to issuer · Disposed 1,083 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,... (Continued in Footnote 3) F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.02 · Expires 2032-05-18 | Direct | 0 |
Reported balance
After 2023-06-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-06-16 · Disposition to issuer · Disposed 21,526 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,... (Continued in Footnote 3) F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 2,174 restricted stock units.
F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,... (Continued in Footnote 3)
F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 22, 2026 Filed May 29, 2026 21:05 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $8.78 | $0.00 |
DisclosureSEC source: 0001493152-26-026429 · ownership.xml · derivative · entry 2 Adams Helen C. · CIK 0001488486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2036-05-22 F2 · derivative.exercise_date: The stock option will vest in substantially equal monthly installments over the 12 months following the date of grant (or, in the event the 2027 Annual Meeting occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the stock option will vest on the date of such 2027 Annual Meeting), subject to the Reporting Person's continued service on the Issuer's Board through the applicable vesting date. Read SEC document |
| May 22, 2026 Filed May 29, 2026 21:05 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | GrantCommon Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-026429 · ownership.xml · nonDerivative · entry 1 Adams Helen C. · CIK 0001488486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,004 F1 · shares: The Reporting Person was granted 6,250 restricted stock units ("RSUs") pursuant to the Issuer's 2021 Equity Incentive Plan, which RSUs will vest in full on the earlier of (i) the one-year anniversary of the date of grant, and (ii) the date that the Issuer's 2027 annual meeting of stockholders (the "2027 Annual Meeting") is held, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| June 20, 2025 Filed Jun 23, 2025 20:57 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | GrantStock Option (Right to Buy) · Derivative | 33,000 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001641172-25-016109 · ownership.xml · derivative · entry 2 Adams Helen C. · CIK 0001488486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,000 Underlying: Common Stock · 33,000 shares Expires 2035-06-20 F1 · derivative.exercise_date: The Stock Option will vest in twelve (12) equal monthly installments following the date of grant, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document |
| June 11, 2024 Filed Jun 21, 2024 21:45 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | GrantStock Option (Right to Buy) · Derivative | 33,000 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0001493152-24-024821 · ownership.xml · derivative · entry 2 Adams Helen C. · CIK 0001488486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,000 Underlying: Common Stock · 33,000 shares Expires 2034-06-11 F1 · derivative.exercise_date: The Stock Option will vest in twelve (12) equal monthly installments following the date of grant, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document |
| May 20, 2024 Filed May 20, 2024 21:25 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | GrantCommon Stock | 74,241 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-24-020777 · ownership.xml · nonDerivative · entry 2 Adams Helen C. · CIK 0001488486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 174,754 F3 · price: Received in exchange for shares of common stock of Nexcella, Inc. which were held by the Reporting Person, which entity was merged with and into the Issuer on May 20, 2024, with the Issuer continuing as the surviving entity. Read SEC document |
| May 15, 2024 Filed May 20, 2024 21:25 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | GrantCommon Stock | 87,740 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-020777 · ownership.xml · nonDerivative · entry 1 Adams Helen C. · CIK 0001488486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,740 F1 · kind: Issued to replace prior awards held by the Reporting Person in Nexcella, Inc., in contemplation of the merger of Nexcella, Inc. and the Issuer, which became effective on May 20, 2024. F2 · shares: Restricted Stock Awards which will vest in thirteen (13) equal monthly installments following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| September 12, 2023 Filed Sep 14, 2023 21:20 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | PurchaseCommon Stock | 13,000 | $2.96 | $38,491.70 |
DisclosureSEC source: 0001493152-23-032664 · ownership.xml · nonDerivative · entry 1 Adams Helen C. · CIK 0001488486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,000 F1 · price: This figure is the weighted average sales price of multiple trades ranging from $2.90 to $3.25 per share. The Reporting Person undertakes to provide the staff of the Securities and Exchange Commission, Immix Biopharma, Inc. or any security holder of Immix Biopharma, Inc. full information about the number of shares sold at each separate price upon request. Read SEC document |
| August 11, 2023 Filed Aug 14, 2023 20:15 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | GrantStock Options · Derivative | 20,000 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001493152-23-028471 · ownership.xml · derivative · entry 1 Adams Helen C. · CIK 0001488486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-08-11 F1 · derivative.exercise_date: Options vest monthly over 12 months from the date of grant. Read SEC document |
| June 16, 2023 Filed Jun 16, 2023 20:00 UTC | Prometheus Biosciences, Inc. RXDX · Entity 112175 | Disposition to issuerStock Option (right to buy) · Derivative | 21,526 | Not disclosed Strike: $29.02 | Not disclosed |
DisclosureSEC source: 0000899243-23-015753 · doc4.xml · derivative · entry 4 Adams Helen C. · CIK 0001488486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,526 shares Expires 2032-05-18 F2 · price: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,... (Continued in Footnote 3) F3 · price: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. F2 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,... (Continued in Footnote 3) F3 · derivative.exercise_date: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. Read SEC document |
| June 16, 2023 Filed Jun 16, 2023 20:00 UTC | Prometheus Biosciences, Inc. RXDX · Entity 112175 | Disposition to issuerStock Option (right to buy) · Derivative | 1,083 | Not disclosed Strike: $36.32 | Not disclosed |
DisclosureSEC source: 0000899243-23-015753 · doc4.xml · derivative · entry 3 Adams Helen C. · CIK 0001488486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,083 shares Expires 2031-11-13 F2 · price: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,... (Continued in Footnote 3) F3 · price: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. F2 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,... (Continued in Footnote 3) F3 · derivative.exercise_date: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. Read SEC document |
| June 16, 2023 Filed Jun 16, 2023 20:00 UTC | Prometheus Biosciences, Inc. RXDX · Entity 112175 | Disposition to issuerStock Option (right to buy) · Derivative | 30,000 | Not disclosed Strike: $6.70 | Not disclosed |
DisclosureSEC source: 0000899243-23-015753 · doc4.xml · derivative · entry 2 Adams Helen C. · CIK 0001488486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2031-02-04 F2 · price: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,... (Continued in Footnote 3) F3 · price: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. F2 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,... (Continued in Footnote 3) F3 · derivative.exercise_date: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. Read SEC document |
| June 16, 2023 Filed Jun 16, 2023 20:00 UTC | Prometheus Biosciences, Inc. RXDX · Entity 112175 | Disposition to issuerCommon Stock | 2,674 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-015753 · doc4.xml · nonDerivative · entry 1 Adams Helen C. · CIK 0001488486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Includes 2,174 restricted stock units. F2 · price: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,... (Continued in Footnote 3) F3 · price: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. Read SEC document |
| May 19, 2023 Filed May 19, 2023 21:38 UTC | Prometheus Biosciences, Inc. RXDX · Entity 112175 | GrantCommon Stock | 2,174 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-031170 · doc4.xml · nonDerivative · entry 1 Adams Helen C. · CIK 0001488486 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,674 F1 · kind: Award of restricted stock units ("RSUs") granted under the Issuer's 2021 Incentive Award Plan (the "2021 Plan"). Each RSU entitles the Reporting Person to receive one share of Issuer common stock upon vesting. The RSUs shall vest in full upon the earlier to occur of (i) the first anniversary of the date of grant, (ii) the Issuer's next occurring annual meeting of stockholders, or (iii) a Change of Control (as defined in the 2021 Plan), subject to the Reporting Person's continued service with the Issuer on such vesting date. Read SEC document |
| July 14, 2022 Filed Jul 18, 2022 10:10 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | GrantStock Options · Derivative | 16,000 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001493152-22-019513 · ownership.xml · derivative · entry 1 Adams Helen C. · CIK 0001488486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,500 Underlying: Common Stock · 16,000 shares Expires 2032-07-14 F1 · derivative.exercise_date: Options vest monthly over 12 months from date of grant. Read SEC document |
| May 19, 2022 Filed May 20, 2022 23:18 UTC | Prometheus Biosciences, Inc. RXDX · Entity 112175 | GrantStock Option (Right to Buy) · Derivative | 21,526 | $0.00 Strike: $29.02 | $0.00 |
DisclosureSEC source: 0001209191-22-031171 · doc4.xml · derivative · entry 1 Adams Helen C. · CIK 0001488486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,526 Underlying: Common Stock · 21,526 shares Expires 2032-05-18 F1 · derivative.exercise_date: The shares subject to the option will vest in full upon the earlier to occur of (i) the first anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service with the Issuer on such vesting date. Read SEC document |
| November 14, 2021 Filed Nov 17, 2021 02:17 UTC | Prometheus Biosciences, Inc. RXDX · Entity 112175 | GrantStock Option (Right to Buy) · Derivative | 1,083 | $0.00 Strike: $36.32 | $0.00 |
DisclosureSEC source: 0001209191-21-064940 · doc4.xml · derivative · entry 1 Adams Helen C. · CIK 0001488486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,083 Underlying: Common Stock · 1,083 shares Expires 2031-11-13 F1 · derivative.exercise_date: The shares subject to the option will vest on the first anniversary of the vesting commencement date measured from November 14, 2021, subject to the Reporting Person's continued service with the Issuer on such vesting date. Read SEC document |
| March 16, 2021 Filed Mar 17, 2021 01:47 UTC | Prometheus Biosciences, Inc. RXDX · Entity 112175 | PurchaseCommon Stock | 500 | $19.00 | $9,500.00 |
DisclosureSEC source: 0001209191-21-021216 · doc4.xml · nonDerivative · entry 1 Adams Helen C. · CIK 0001488486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.